Life-changing MS drugs to stay on the PBS. So why are others under threat - and how is Trump involved?
The Australian government has confirmed that three key multiple sclerosis drugs will remain on the Pharmaceutical Benefits Scheme (PBS) following a pricing dispute. An expert advisory panel will conduct a rapid review of the drugs before a final decision is made later this year.
Why it matters
This decision prevents thousands of patients from facing significant out-of-pocket costs for essential life-saving medication.
The federal government says key drugs for multiple sclerosis will continue to receive taxpayer subsidies. It comes after pharmaceutical companies have pulled some drugs from the PBS in recent months. Photograph: AAP The federal government says key drugs for multiple sclerosis will continue to receive taxpayer subsidies. It comes after pharmaceutical companies have pulled some drugs from the PBS in recent months. Photograph: AAP Health Explainer Life-changing MS drugs to stay on the PBS. So why are others under threat – and how is Trump involved? Health minister Mark Butler confirms Ocrevus, Kesimpta and Lemtrada will stay subsidised amid questions about the Pharmaceutical Benefits Scheme
The article reports on government policy and industry negotiations using neutral, factual language without clear partisan slant.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in